 [1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CLONAZEPAM increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does CLONAZEPAM increase or decrease the risk of bleeding?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes CLONAZEPAM increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CLONAZEPAM increase or decrease the risk of bleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does CLONAZEPAM increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"CLONAZEPAM"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: CLONAZEPAM: spl_medguide: Do not suddenly stop taking clonazepam tablets. Stopping clonazepam tablets suddenly can cause serious and life-threatening side effects, including, unusual [0m
[31mmovements, responses, or expressions, seizures, sudden and severe mental or nervous system changes, depression, seeing or hearing things that others do not see or hear, an extreme increase in activity[0m
[31mor talking, losing touch with reality, and suicidal thoughts or actions. Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these symptoms. Some [0m
[31mpeople who suddenly stop benzodiazepines have symptoms that can last for several weeks to more than [0m[1;31m12[0m[31m months , including, anxiety, trouble remembering, learning, or concentrating, depression, [0m
[31mproblems sleeping, feeling like insects are crawling under your skin, weakness, shaking, muscle twitching, burning or prickling feeling in your hands, arms, legs or feet, and ringing in your ears. [0m
[31mPhysical dependence is not the same as drug addiction. CLONAZEPAM: spl_medguide: Your healthcare provider can tell you more about the differences between physical dependence and drug addiction. Do not[0m
[31mtake more clonazepam tablets than prescribed or take clonazepam tablets for longer than prescribed. Clonazepam tablets can make you sleepy or dizzy and can slow your thinking and motor skills. This [0m
[31mmay get better over time. Do not drive, operate heavy machinery, or do other dangerous activities until you know how clonazepam tablets affect you. Clonazepam tablets may cause problems with your [0m
[31mcoordination, especially when you are walking or picking things up. Do not drink alcohol or take other drugs that may make you sleepy or dizzy while taking clonazepam tablets until you talk to your [0m
[31mhealthcare provider. When taken with alcohol or drugs that cause sleepiness or dizziness, clonazepam tablets may make your sleepiness or dizziness worse. CLONAZEPAM: spl_medguide: Like other [0m
[31mantiepileptic medicines, clonazepam tablets may cause suicidal thoughts or actions in a very small number of people, about [0m[1;31m1[0m[31m in [0m[1;31m500[0m[31m. Call your healthcare provider right away if you have any of these [0m
[31msymptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying attempts to commit suicide new or worse depression new or worse anxiety feeling agitated or restless panic [0m
[31mattacks trouble sleeping [0m[1;31m([0m[31minsomnia[0m[1;31m)[0m[31m acting on dangerous impulses new or worse irritability an extreme increase in activity and talking [0m[1;31m([0m[31mmania[0m[1;31m)[0m[31m acting aggressive, being angry, or violent other unusual [0m
[31mchanges in behavior or mood How can I watch for early symptoms of suicidal thoughts and actions? Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. [0m
[31mKeep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you are worried about symptoms. CLONAZEPAM: spl_medguide: [0m
[31mSuicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes. Do not stop clonazepam tablets[0m
[31mwithout first talking to a healthcare provider. Stopping clonazepam tablets suddenly can cause serious problems. Stopping clonazepam tablets suddenly can cause seizures that will not stop [0m[1;31m([0m[31mstatus [0m
[31mepilepticus[0m[1;31m)[0m[31m. What are clonazepam tablets? Clonazepam tablets are a prescription medicine used alone or with other medicines to treat: certain types of seizure disorders [0m[1;31m([0m[31mepilepsy[0m[1;31m)[0m[31m in adults and [0m
[31mchildren panic disorder with or without fear of open spaces [0m[1;31m([0m[31magoraphobia[0m[1;31m)[0m[31m in adults Clonazepam tablets are a federally controlled substance [0m[1;31m([0m[31mC-IV[0m[1;31m)[0m[31m because it contains clonazepam that can be abused or [0m
[31mlead to dependence. Keep clonazepam tablets in a safe place to prevent misuse and abuse. CLONAZEPAM: spl_medguide: Selling or giving away clonazepam tablets may harm others, and is against the law. [0m
[31mTell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs. It is not known if clonazepam tablets are safe or effective in treating [0m
[31mpanic disorder in children younger than [0m[1;31m18[0m[31m years old. Who should not take clonazepam tablets? Do not take clonazepam tablets if you: are allergic to benzodiazepines have significant liver disease have[0m
[31man eye disease called acute narrow angle glaucoma Ask your healthcare provider if you are not sure if you have any of the problems listed above. Before you take clonazepam tablets, tell your [0m
[31mhealthcare provider if you: have liver or kidney problems have lung problems [0m[1;31m([0m[31mrespiratory disease[0m[1;31m)[0m[31m have or have had depression, mood problems, or suicidal thoughts or behavior have any other medical [0m
[31mproblems are pregnant or plan to become pregnant.         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: adverse_reactions: While these findings are noteworthy, Hamilton Depression Rating Scale [0m[1;31m([0m[31mHAM-D[0m[1;31m)[0m[31m data collected in these trials revealed a larger decline in HAM-D scores in the [0m
[31mclonazepam group than the placebo group suggesting that clonazepam-treated patients were not experiencing a worsening or emergence of clinical depression. Other Adverse Events Observed During the [0m
[31mPremarketing Evaluation of Clonazepam Tablets in Panic Disorder: Following is a list of modified CIGY terms that reflect treatment-emergent adverse events reported by patients treated with clonazepam [0m
[31mtablets at multiple doses during clinical trials. All reported events are included except those already listed in Table [0m[1;31m3[0m[31m or elsewhere in labeling, those events for which a drug cause was remote, [0m
[31mthose event terms which were so general as to be uninformative, and events reported only once and which did not have a substantial probability of being acutely life-threatening. CLONAZEPAM: [0m
[31madverse_reactions: It is important to emphasize that, although the events occurred during treatment with clonazepam tablets, they were not necessarily caused by it. Events are further categorized by [0m
[31mbody system and listed in order of decreasing frequency. These adverse events were reported infrequently, which is defined as occurring in [0m[1;31m1[0m[31m/[0m[1;31m100[0m[31m to [0m[1;31m1[0m[31m/[0m[1;31m1000[0m[31m patients. CLONAZEPAM: adverse_reactions: Body[0m
[31mas a Whole: weight increase, accident, weight decrease, wound, edema, fever, shivering, abrasions, ankle edema, edema foot, edema periorbital, injury, malaise, pain, cellulitis, inflammation localized[0m
[31mCardiovascular Disorders: chest pain, hypotension postural Central and Peripheral Nervous System Disorders: migraine, paresthesia, drunkenness, feeling of enuresis, paresis, tremor, burning skin, [0m
[31mfalling, head fullness, hoarseness, hyperactivity, hypoesthesia, tongue thick, twitching Gastrointestinal System Disorders: abdominal discomfort, gastrointestinal inflammation, stomach upset, [0m
[31mtoothache, flatulence, pyrosis, saliva increased, tooth disorder, bowel movements frequent, pain pelvic, dyspepsia, hemorrhoids Hearing and Vestibular Disorders: vertigo, otitis, earache, motion [0m
[31msickness Heart Rate and Rhythm Disorders: palpitation Metabolic and Nutritional Disorders: thirst CLONAZEPAM: adverse_reactions: , gout Musculoskeletal System Disorders: back pain, fracture traumatic,[0m
[31msprains and strains, pain leg, pain nape, cramps muscle, cramps leg, pain ankle, pain shoulder, tendinitis, arthralgia, hypertonia, lumbago, pain feet, pain jaw, pain knee, swelling knee Platelet, [0m
[31mBleeding and Clotting Disorders: bleeding dermal Psychiatric Disorders: insomnia, organic disinhibition, anxiety, depersonalization, dreaming excessive, libido loss, appetite increased, libido [0m
[31mincreased, reactions decreased, aggression, apathy, disturbance in attention, excitement, anger, hunger abnormal, illusion, nightmares, sleep disorder, suicide ideation, yawning Reproductive [0m
[31mDisorders, Female: breast pain, menstrual irregularity Reproductive Disorders, Male: ejaculation decreased Resistance Mechanism Disorders: infection mycotic, infection viral, infection streptococcal, [0m
[31mherpes simplex infection, infectious mononucleosis, moniliasis Respir CLONAZEPAM: adverse_reactions: atory System Disorders: sneezing excessive, asthmatic attack, dyspnea, nosebleed, pneumonia, [0m
[31mpleurisy Skin and Appendages Disorders: acne flare, alopecia, xeroderma, dermatitis contact, flushing, pruritus, pustular reaction, skin burns, skin disorder Special Senses Other, Disorders: taste [0m
[31mloss Urinary System Disorders: dysuria, cystitis, polyuria, urinary incontinence, bladder dysfunction, urinary retention, urinary tract bleeding, urine discoloration Vascular [0m[1;31m([0m[31mExtracardiac[0m[1;31m)[0m[31m Disorders:[0m
[31mthrombophlebitis leg Vision Disorders: eye irritation, visual disturbance, diplopia, eye twitching, styes, visual field defect, xerophthalmia         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: dosage_and_administration: In general, elderly patients should be started on low doses of clonazepam tablets and observed closely [0m[1;31m([0m[31msee PRECAUTIONS: Geriatric Use [0m[1;31m)[0m[31m. Panic [0m
[31mDisorder: Adults: The initial dose for adults with panic disorder is [0m[1;31m0.25[0m[31m mg twice daily. An increase to the target dose for most patients of [0m[1;31m1[0m[31m mg/day may be made after [0m[1;31m3[0m[31m days. The recommended dose of[0m
[1;31m1[0m[31m mg/day is based on the results from a fixed dose study in which the optimal effect was seen at [0m[1;31m1[0m[31m mg/day. Higher doses of [0m[1;31m2[0m[31m, [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m mg/day in that study were less effective than the [0m[1;31m1[0m[31m mg/day dose [0m
[31mand were associated with more adverse effects. Nevertheless, it is possible that some individual patients may benefit from doses of up to a maximum dose of [0m[1;31m4[0m[31m mg/day, and in those instances, the dose [0m
[31mmay be increased in increments of [0m[1;31m0.125[0m[31m to [0m[1;31m0[0m[31m. CLONAZEPAM: dosage_and_administration: [0m[1;31m25[0m[31m mg twice daily every [0m[1;31m3[0m[31m days until panic disorder is controlled or until side effects make further increases [0m
[31mundesired. To reduce the inconvenience of somnolence, administration of one dose at bedtime may be desirable. Treatment should be discontinued gradually, with a decrease of [0m[1;31m0.125[0m[31m mg twice daily every [0m
[1;31m3[0m[31m days, until the drug is completely withdrawn. There is no body of evidence available to answer the question of how long the patient treated with clonazepam should remain on it. Therefore, the [0m
[31mphysician who elects to use clonazepam tablets for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. Pediatric Patients: There is no [0m
[31mclinical trial experience with clonazepam tablets in panic disorder patients under [0m[1;31m18[0m[31m years of age. Geriatric Patients: There is no clinical trial experience with clonazepam tablets in panic disorder [0m
[31mpatients [0m[1;31m65[0m[31m years of age and older. CLONAZEPAM: dosage_and_administration: In general, elderly patients should be started on low doses of clonazepam tablets and observed closely [0m[1;31m([0m[31msee PRECAUTIONS: [0m
[31mGeriatric Use [0m[1;31m)[0m[31m. Discontinuation or Dosage Reduction of Clonazepam Tablets: To reduce the risk of withdrawal reactions, increased seizure frequency, and status epilepticus, use a gradual taper to [0m
[31mdiscontinue clonazepam tablets or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level. Subsequently [0m
[31mdecrease the dosage more slowly [0m[1;31m([0m[31msee WARNINGS: Dependence and Withdrawal Reactions and DRUG ABUSE AND DEPENDENCE: Dependence [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: openfda: pharm_class_cs         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: openfda: product_ndc         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: warnings: WARNINGS Risks from Concomitant Use with Opioids: Concomitant use of benzodiazepines, including clonazepam tablets, and opioids may result in profound sedation, [0m
[31mrespiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of benzodiazepines and opioids for patients for whom alternative treatment options are inadequate. [0m
[31mObservational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is [0m
[31mmade to prescribe clonazepam tablets concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of [0m
[31mrespiratory depression and sedation. CLONAZEPAM: warnings: Advise both patients and caregivers about the risks of respiratory depression and sedation when clonazepam tablets are used with opioids [0m[1;31m([0m[31msee[0m
[31mPRECAUTIONS: Information for Patients and PRECAUTIONS: Drug Interactions [0m[1;31m)[0m[31m. Abuse, Misuse, and Addiction: The use of benzodiazepines, including clonazepam tablets, exposes users to the risks of abuse,[0m
[31mmisuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often [0m[1;31m([0m[31mbut not always[0m[1;31m)[0m[31m involve the use of doses greater than the maximum recommended dosage and commonly[0m
[31minvolve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, [0m
[31moverdose, or death [0m[1;31m([0m[31msee DRUG ABUSE AND DEPENDENCE: Abuse [0m[1;31m)[0m[31m . Before prescribing clonazepam tablets and throughout treatment, assess each patientâ€™s risk for abuse, misuse, and addiction [0m[1;31m([0m[31me.g. [0m
[31mCLONAZEPAM: warnings: using a standardized screening tool[0m[1;31m)[0m[31m. Use of clonazepam tablets, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of clonazepam [0m
[31mtablets along with monitoring for signs and symptoms of abuse, misuse, and addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances [0m
[31massociated with abuse, misuse, and addiction [0m[1;31m([0m[31me.g., opioid analgesics, stimulants[0m[1;31m)[0m[31m; and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the [0m
[31mpatient and institute [0m[1;31m([0m[31mor refer them for[0m[1;31m)[0m[31m early treatment, as appropriate. Dependence and Withdrawal Reactions: To reduce the risk of withdrawal reactions, use a gradual taper to discontinue [0m
[31mclonazepam tablets or reduce the dosage [0m[1;31m([0m[31ma patient-specific plan should be used to taper the dose[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION: Discontinuation or Dosage Reduction of Clonazepam Tablets [0m[1;31m)[0m[31m .        [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: boxed_warning: WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and [0m
[31mopioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. [0m
[31mLimit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [0m[1;31m([0m[31msee WARNINGS and PRECAUTIONS [0m[1;31m)[0m[31m. The use of benzodiazepines, [0m
[31mincluding clonazepam tablets, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other[0m
[31mmedications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. CLONAZEPAM: boxed_warning: Before prescribing clonazepam tablets and [0m
[31mthroughout treatment, assess each patientâ€™s risk for abuse, misuse, and addiction [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m . The continued use of benzodiazepines, including clonazepam tablets, may lead to clinically [0m
[31msignificant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of clonazepam [0m
[31mtablets after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue clonazepam tablets[0m
[31mor reduce the dosage [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION and WARNINGS [0m[1;31m)[0m[31m .         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: spl_medguide_table: [0m[1;31m<[0m[1;31mcontent[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these [0m
[31msymptoms.<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mitem[0m[31m><item><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Some people who suddenly stop benzodiazepines have symptoms that can last for several weeks to more than [0m[1;31m12[0m[31m months<[0m[31m/[0m[31mcontent[0m[31m>, including, [0m
[31manxiety, trouble remembering, learning, or concentrating, depression, problems sleeping, feeling like insects are crawling under your skin, weakness, shaking, muscle twitching, burning or prickling [0m
[31mfeeling in your hands, arms, legs or feet, and ringing in your ears. <[0m[31m/[0m[31mitem[0m[31m><item>Physical dependence is not the same as drug addiction. Your healthcare provider can tell you more about the [0m
[31mdifferences between physical dependence and drug addiction.<[0m[31m/[0m[31mitem[0m[31m><item>Do not take more clonazepam tablets than prescribed or take clonazepam tablets for longer than prescribed. CLONAZEPAM: [0m
[31mspl_medguide_table: <list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disc"[0m[31m><item><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Clonazepam tablets can make you sleepy or dizzy and can slow your thinking and motor skills. This may [0m
[31mget better over time.<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mitem[0m[31m><item>Do not drive, operate heavy machinery, or do other dangerous activities until you know how clonazepam tablets affect you. <content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m/[0m[31m><[0m[31m/[0m[31mitem[0m[31m><item>Clonazepam tablets may cause problems with your coordination, especially when you are walking or picking things up. <content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m/[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m
[31mstyleCode[0m[31m=[0m[31m"Disc"[0m[31m><item><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Do not drink alcohol or take other drugs that may make you sleepy or dizzy while taking clonazepam tablets until you talk to your healthcare [0m
[31mprovider.<[0m[31m/[0m[31mcontent[0m[31m>When taken with alcohol or drugs that cause sleepiness or dizziness, clonazepam tablets may make your sleepiness or dizziness worse. CLONAZEPAM: spl_medguide_table: <content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m/[0m[31m><[0m[31m/[0m[31mitem[0m[31m><item><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Like other antiepileptic medicines, clonazepam tablets may cause suicidal thoughts or actions in a very small number of people, about [0m[1;31m1[0m[31m in [0m[1;31m500[0m[31m.[0m
[31mCLONAZEPAM: spl_medguide_table: content><[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Call your healthcare provider right away if you have any of these symptoms, [0m
[31mespecially if they are new, worse, or worry you:<[0m[31m/[0m[31mcontent[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr [0m[31mstyleCode[0m[31m=[0m[31m"Botrule"[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disc"[0m[31m><item>thoughts about [0m
[31msuicide or dying<[0m[31m/[0m[31mitem[0m[31m><item>attempts to commit suicide<[0m[31m/[0m[31mitem[0m[31m><item>new or worse depression<[0m[31m/[0m[31mitem[0m[31m><item>new or worse anxiety<[0m[31m/[0m[31mitem[0m[31m><item>feeling agitated or restless<[0m[31m/[0m[31mitem[0m[31m><item>panic [0m
[31mattacks<[0m[31m/[0m[31mitem[0m[31m><item>trouble sleeping [0m[1;31m([0m[31minsomnia[0m[1;31m)[0m[31m<[0m[31m/[0m[31mitem[0m[31m><item>acting on dangerous impulses<[0m[31m/[0m[31mitem[0m[31m><item>new or worse irritability<[0m[31m/[0m[31mitem[0m[31m><item>an extreme increase in activity and talking [0m
[1;31m([0m[31mmania[0m[1;31m)[0m[31m<[0m[31m/[0m[31mitem[0m[31m><item>acting aggressive, being angry, or violent<[0m[31m/[0m[31m CLONAZEPAM: spl_medguide_table: item><item>other unusual changes in behavior or mood<[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr [0m[31mstyleCode[0m[31m=[0m[31m"Botrule"[0m[31m><td[0m
[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>How can I watch for early symptoms of suicidal thoughts and actions?<[0m[31m/[0m[31mcontent[0m[31m> <list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disc"[0m[31m><item>Pay [0m
[31mattention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings.<[0m[31m/[0m[31mitem[0m[31m><item>Keep all follow-up visits with your healthcare provider as scheduled.<[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[1;31m>[0m[31mCall your[0m
[31mhealthcare provider between visits as needed, especially if you are worried about symptoms. Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or [0m
[31mactions, your healthcare provider may check for other causes.         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: warnings: Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages, and [0m
[31mthose who have had longer durations of use. Acute Withdrawal Reactions The continued use of benzodiazepines, including clonazepam tablets, may lead to clinically significant physical dependence. [0m
[31mAbrupt discontinuation or rapid dosage reduction of clonazepam tablets after continued use, or administration of flumazenil [0m[1;31m([0m[31ma benzodiazepine antagonist[0m[1;31m)[0m[31m may precipitate acute withdrawal reactions, [0m
[31mwhich can be life-threatening [0m[1;31m([0m[31me.g., seizures[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee DRUG ABUSE AND DEPENDENCE: Dependence [0m[1;31m)[0m[31m . Protracted Withdrawal Syndrome In some cases, benzodiazepine users have developed a protracted withdrawal [0m
[31msyndrome with withdrawal symptoms lasting weeks to more than [0m[1;31m12[0m[31m months [0m[1;31m([0m[31msee DRUG ABUSE AND DEPENDENCE: Dependence [0m[1;31m)[0m[31m. CLONAZEPAM: warnings: Interference with Cognitive and Motor Performance: Since [0m
[31mclonazepam tablets produce CNS depression, patients receiving this drug should be cautioned against engaging in hazardous occupations requiring mental alertness, such as operating machinery or driving[0m
[31ma motor vehicle. They should also be warned about the concomitant use of alcohol or other CNS-depressant drugs during clonazepam tablets therapy [0m[1;31m([0m[31msee PRECAUTIONS: Drug Interactions and PRECAUTIONS: [0m
[31mInformation for Patients [0m[1;31m)[0m[31m. Suicidal Behavior and Ideation: Antiepileptic drugs [0m[1;31m([0m[31mAEDs[0m[1;31m)[0m[31m, including clonazepam tablets, increase the risk of suicidal thoughts or behavior in patients taking these drugs [0m
[31mfor any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood[0m
[31mor behavior. CLONAZEPAM: warnings: Pooled analyses of [0m[1;31m199[0m[31m placebo-controlled clinical trials [0m[1;31m([0m[31mmono- and adjunctive therapy[0m[1;31m)[0m[31m of [0m[1;31m11[0m[31m different AEDs showed that patients randomized to one of the AEDs had [0m
[31mapproximately twice the risk [0m[1;31m([0m[31madjusted Relative Risk [0m[1;31m1.8[0m[31m, [0m[1;31m95[0m[31m% CI:[0m[1;31m1.2[0m[31m, [0m[1;31m2.7[0m[1;31m)[0m[31m of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment [0m
[31mduration of [0m[1;31m12[0m[31m weeks, the estimated incidence rate of suicidal behavior or ideation among [0m[1;31m27[0m[31m,[0m[1;31m863[0m[31m AED-treated patients was [0m[1;31m0.43[0m[31m% compared to [0m[1;31m0.24[0m[31m% among [0m[1;31m16[0m[31m,[0m[1;31m029[0m[31m placebo-treated patients, representing an[0m
[31mincrease of approximately one case of suicidal thinking or behavior for every [0m[1;31m530[0m[31m patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated [0m
[31mpatients, but the number is too small to allow any conclusion about drug effect on suicide. CLONAZEPAM: warnings: The increased risk of suicidal thoughts or behavior with AEDs was observed as early as[0m
[31mone week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond [0m[1;31m24[0m[31m weeks, the risk of suicidal[0m
[31mthoughts or behavior beyond [0m[1;31m24[0m[31m weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs[0m
[31mof varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age [0m[1;31m([0m[1;31m5[0m[31m to [0m[1;31m100[0m[31m years[0m[1;31m)[0m[31m in the[0m
[31mclinical trials analyzed. Table [0m[1;31m1[0m[31m shows absolute and relative risk by indication for all evaluated AEDs. Table [0m[1;31m1[0m[31m. CLONAZEPAM: warnings: Risk by Indication for Antiepileptic Drugs in the Pooled [0m
[31mAnalysis Indication Placebo Drug Patients Relative Risk: Risk Difference: Patients with with Events Per Incidence of Additional Drug Events Per [0m[1;31m1000[0m[31m Patients Events in Drug Patients with [0m[1;31m1000[0m[31m Patients[0m
[31mPatients/Incidence Events per [0m[1;31m1000[0m[31m in Placebo Patients Patients Epilepsy [0m[1;31m1.0[0m[31m [0m[1;31m3.4[0m[31m [0m[1;31m3.5[0m[31m [0m[1;31m2.4[0m[31m Psychiatric [0m[1;31m5.7[0m[31m [0m[1;31m8.5[0m[31m [0m[1;31m1.5[0m[31m [0m[1;31m2.9[0m[31m Other [0m[1;31m1.0[0m[31m [0m[1;31m1.8[0m[31m [0m[1;31m1.9[0m[31m [0m[1;31m0.9[0m[31m Total [0m[1;31m2.4[0m[31m [0m[1;31m4.3[0m[31m [0m[1;31m1.8[0m[31m [0m[1;31m1.9[0m[31m The relative risk for suicidal thoughts[0m
[31mor behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric [0m
[31mindications. CLONAZEPAM: warnings: Anyone considering prescribing clonazepam tablets or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. [0m
[31mEpilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and with an increased risk of suicidal thoughts and behavior. Should suicidal [0m
[31mthoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated. Patients, [0m
[31mtheir caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the [0m
[31msigns and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported [0m
[31mimmediately to healthcare providers. CLONAZEPAM: warnings: Neonatal Sedation and Withdrawal Syndrome: Use of clonazepam tablets late in pregnancy can result in sedation [0m[1;31m([0m[31mrespiratory depression, [0m
[31mlethargy, hypotonia[0m[1;31m)[0m[31m and/or withdrawal symptoms [0m[1;31m([0m[31mhyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties[0m[1;31m)[0m[31m in the neonate [0m[1;31m([0m[31msee PRECAUTIONS: Pregnancy [0m[1;31m)[0m[31m. [0m
[31mMonitor neonates exposed to clonazepam tablets during pregnancy or labor for signs of sedation and monitor neonates exposed to clonazepam tablets during pregnancy for signs of withdrawal; manage these[0m
[31mneonates accordingly.         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does CLONAZEPAM increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"CLONAZEPAM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does CLONAZEPAM increase or decrease the risk of [0m
[31mbleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does CLONAZEPAM increase or decrease the risk of bleeding?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes CLONAZEPAM increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CLONAZEPAM increase or decrease the risk of bleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does CLONAZEPAM increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"CLONAZEPAM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: CLONAZEPAM: spl_medguide: Do not suddenly stop taking clonazepam tablets. Stopping clonazepam tablets suddenly can cause serious and life-threatening side effects, including, unusual [0m
[31mmovements, responses, or expressions, seizures, sudden and severe mental or nervous system changes, depression, seeing or hearing things that others do not see or hear, an extreme increase in activity[0m
[31mor talking, losing touch with reality, and suicidal thoughts or actions. Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these symptoms. Some [0m
[31mpeople who suddenly stop benzodiazepines have symptoms that can last for several weeks to more than [0m[1;31m12[0m[31m months , including, anxiety, trouble remembering, learning, or concentrating, depression, [0m
[31mproblems sleeping, feeling like insects are crawling under your skin, weakness, shaking, muscle twitching, burning or prickling feeling in your hands, arms, legs or feet, and ringing in your ears. [0m
[31mPhysical dependence is not the same as drug addiction. CLONAZEPAM: spl_medguide: Your healthcare provider can tell you more about the differences between physical dependence and drug addiction. Do not[0m
[31mtake more clonazepam tablets than prescribed or take clonazepam tablets for longer than prescribed. Clonazepam tablets can make you sleepy or dizzy and can slow your thinking and motor skills. This [0m
[31mmay get better over time. Do not drive, operate heavy machinery, or do other dangerous activities until you know how clonazepam tablets affect you. Clonazepam tablets may cause problems with your [0m
[31mcoordination, especially when you are walking or picking things up. Do not drink alcohol or take other drugs that may make you sleepy or dizzy while taking clonazepam tablets until you talk to your [0m
[31mhealthcare provider. When taken with alcohol or drugs that cause sleepiness or dizziness, clonazepam tablets may make your sleepiness or dizziness worse. CLONAZEPAM: spl_medguide: Like other [0m
[31mantiepileptic medicines, clonazepam tablets may cause suicidal thoughts or actions in a very small number of people, about [0m[1;31m1[0m[31m in [0m[1;31m500[0m[31m. Call your healthcare provider right away if you have any of these [0m
[31msymptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying attempts to commit suicide new or worse depression new or worse anxiety feeling agitated or restless panic [0m
[31mattacks trouble sleeping [0m[1;31m([0m[31minsomnia[0m[1;31m)[0m[31m acting on dangerous impulses new or worse irritability an extreme increase in activity and talking [0m[1;31m([0m[31mmania[0m[1;31m)[0m[31m acting aggressive, being angry, or violent other unusual [0m
[31mchanges in behavior or mood How can I watch for early symptoms of suicidal thoughts and actions? Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. [0m
[31mKeep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you are worried about symptoms. CLONAZEPAM: spl_medguide: [0m
[31mSuicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes. Do not stop clonazepam tablets[0m
[31mwithout first talking to a healthcare provider. Stopping clonazepam tablets suddenly can cause serious problems. Stopping clonazepam tablets suddenly can cause seizures that will not stop [0m[1;31m([0m[31mstatus [0m
[31mepilepticus[0m[1;31m)[0m[31m. What are clonazepam tablets? Clonazepam tablets are a prescription medicine used alone or with other medicines to treat: certain types of seizure disorders [0m[1;31m([0m[31mepilepsy[0m[1;31m)[0m[31m in adults and [0m
[31mchildren panic disorder with or without fear of open spaces [0m[1;31m([0m[31magoraphobia[0m[1;31m)[0m[31m in adults Clonazepam tablets are a federally controlled substance [0m[1;31m([0m[31mC-IV[0m[1;31m)[0m[31m because it contains clonazepam that can be abused or [0m
[31mlead to dependence. Keep clonazepam tablets in a safe place to prevent misuse and abuse. CLONAZEPAM: spl_medguide: Selling or giving away clonazepam tablets may harm others, and is against the law. [0m
[31mTell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs. It is not known if clonazepam tablets are safe or effective in treating [0m
[31mpanic disorder in children younger than [0m[1;31m18[0m[31m years old. Who should not take clonazepam tablets? Do not take clonazepam tablets if you: are allergic to benzodiazepines have significant liver disease have[0m
[31man eye disease called acute narrow angle glaucoma Ask your healthcare provider if you are not sure if you have any of the problems listed above. Before you take clonazepam tablets, tell your [0m
[31mhealthcare provider if you: have liver or kidney problems have lung problems [0m[1;31m([0m[31mrespiratory disease[0m[1;31m)[0m[31m have or have had depression, mood problems, or suicidal thoughts or behavior have any other medical [0m
[31mproblems are pregnant or plan to become pregnant.         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: adverse_reactions: While these findings are noteworthy, Hamilton Depression Rating Scale [0m[1;31m([0m[31mHAM-D[0m[1;31m)[0m[31m data collected in these trials revealed a larger decline in HAM-D scores in the [0m
[31mclonazepam group than the placebo group suggesting that clonazepam-treated patients were not experiencing a worsening or emergence of clinical depression. Other Adverse Events Observed During the [0m
[31mPremarketing Evaluation of Clonazepam Tablets in Panic Disorder: Following is a list of modified CIGY terms that reflect treatment-emergent adverse events reported by patients treated with clonazepam [0m
[31mtablets at multiple doses during clinical trials. All reported events are included except those already listed in Table [0m[1;31m3[0m[31m or elsewhere in labeling, those events for which a drug cause was remote, [0m
[31mthose event terms which were so general as to be uninformative, and events reported only once and which did not have a substantial probability of being acutely life-threatening. CLONAZEPAM: [0m
[31madverse_reactions: It is important to emphasize that, although the events occurred during treatment with clonazepam tablets, they were not necessarily caused by it. Events are further categorized by [0m
[31mbody system and listed in order of decreasing frequency. These adverse events were reported infrequently, which is defined as occurring in [0m[1;31m1[0m[31m/[0m[1;31m100[0m[31m to [0m[1;31m1[0m[31m/[0m[1;31m1000[0m[31m patients. CLONAZEPAM: adverse_reactions: Body[0m
[31mas a Whole: weight increase, accident, weight decrease, wound, edema, fever, shivering, abrasions, ankle edema, edema foot, edema periorbital, injury, malaise, pain, cellulitis, inflammation localized[0m
[31mCardiovascular Disorders: chest pain, hypotension postural Central and Peripheral Nervous System Disorders: migraine, paresthesia, drunkenness, feeling of enuresis, paresis, tremor, burning skin, [0m
[31mfalling, head fullness, hoarseness, hyperactivity, hypoesthesia, tongue thick, twitching Gastrointestinal System Disorders: abdominal discomfort, gastrointestinal inflammation, stomach upset, [0m
[31mtoothache, flatulence, pyrosis, saliva increased, tooth disorder, bowel movements frequent, pain pelvic, dyspepsia, hemorrhoids Hearing and Vestibular Disorders: vertigo, otitis, earache, motion [0m
[31msickness Heart Rate and Rhythm Disorders: palpitation Metabolic and Nutritional Disorders: thirst CLONAZEPAM: adverse_reactions: , gout Musculoskeletal System Disorders: back pain, fracture traumatic,[0m
[31msprains and strains, pain leg, pain nape, cramps muscle, cramps leg, pain ankle, pain shoulder, tendinitis, arthralgia, hypertonia, lumbago, pain feet, pain jaw, pain knee, swelling knee Platelet, [0m
[31mBleeding and Clotting Disorders: bleeding dermal Psychiatric Disorders: insomnia, organic disinhibition, anxiety, depersonalization, dreaming excessive, libido loss, appetite increased, libido [0m
[31mincreased, reactions decreased, aggression, apathy, disturbance in attention, excitement, anger, hunger abnormal, illusion, nightmares, sleep disorder, suicide ideation, yawning Reproductive [0m
[31mDisorders, Female: breast pain, menstrual irregularity Reproductive Disorders, Male: ejaculation decreased Resistance Mechanism Disorders: infection mycotic, infection viral, infection streptococcal, [0m
[31mherpes simplex infection, infectious mononucleosis, moniliasis Respir CLONAZEPAM: adverse_reactions: atory System Disorders: sneezing excessive, asthmatic attack, dyspnea, nosebleed, pneumonia, [0m
[31mpleurisy Skin and Appendages Disorders: acne flare, alopecia, xeroderma, dermatitis contact, flushing, pruritus, pustular reaction, skin burns, skin disorder Special Senses Other, Disorders: taste [0m
[31mloss Urinary System Disorders: dysuria, cystitis, polyuria, urinary incontinence, bladder dysfunction, urinary retention, urinary tract bleeding, urine discoloration Vascular [0m[1;31m([0m[31mExtracardiac[0m[1;31m)[0m[31m Disorders:[0m
[31mthrombophlebitis leg Vision Disorders: eye irritation, visual disturbance, diplopia, eye twitching, styes, visual field defect, xerophthalmia         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: dosage_and_administration: In general, elderly patients should be started on low doses of clonazepam tablets and observed closely [0m[1;31m([0m[31msee PRECAUTIONS: Geriatric Use [0m[1;31m)[0m[31m. Panic [0m
[31mDisorder: Adults: The initial dose for adults with panic disorder is [0m[1;31m0.25[0m[31m mg twice daily. An increase to the target dose for most patients of [0m[1;31m1[0m[31m mg/day may be made after [0m[1;31m3[0m[31m days. The recommended dose of[0m
[1;31m1[0m[31m mg/day is based on the results from a fixed dose study in which the optimal effect was seen at [0m[1;31m1[0m[31m mg/day. Higher doses of [0m[1;31m2[0m[31m, [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m mg/day in that study were less effective than the [0m[1;31m1[0m[31m mg/day dose [0m
[31mand were associated with more adverse effects. Nevertheless, it is possible that some individual patients may benefit from doses of up to a maximum dose of [0m[1;31m4[0m[31m mg/day, and in those instances, the dose [0m
[31mmay be increased in increments of [0m[1;31m0.125[0m[31m to [0m[1;31m0[0m[31m. CLONAZEPAM: dosage_and_administration: [0m[1;31m25[0m[31m mg twice daily every [0m[1;31m3[0m[31m days until panic disorder is controlled or until side effects make further increases [0m
[31mundesired. To reduce the inconvenience of somnolence, administration of one dose at bedtime may be desirable. Treatment should be discontinued gradually, with a decrease of [0m[1;31m0.125[0m[31m mg twice daily every [0m
[1;31m3[0m[31m days, until the drug is completely withdrawn. There is no body of evidence available to answer the question of how long the patient treated with clonazepam should remain on it. Therefore, the [0m
[31mphysician who elects to use clonazepam tablets for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. Pediatric Patients: There is no [0m
[31mclinical trial experience with clonazepam tablets in panic disorder patients under [0m[1;31m18[0m[31m years of age. Geriatric Patients: There is no clinical trial experience with clonazepam tablets in panic disorder [0m
[31mpatients [0m[1;31m65[0m[31m years of age and older. CLONAZEPAM: dosage_and_administration: In general, elderly patients should be started on low doses of clonazepam tablets and observed closely [0m[1;31m([0m[31msee PRECAUTIONS: [0m
[31mGeriatric Use [0m[1;31m)[0m[31m. Discontinuation or Dosage Reduction of Clonazepam Tablets: To reduce the risk of withdrawal reactions, increased seizure frequency, and status epilepticus, use a gradual taper to [0m
[31mdiscontinue clonazepam tablets or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level. Subsequently [0m
[31mdecrease the dosage more slowly [0m[1;31m([0m[31msee WARNINGS: Dependence and Withdrawal Reactions and DRUG ABUSE AND DEPENDENCE: Dependence [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: openfda: pharm_class_cs         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: openfda: product_ndc         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: warnings: WARNINGS Risks from Concomitant Use with Opioids: Concomitant use of benzodiazepines, including clonazepam tablets, and opioids may result in profound sedation, [0m
[31mrespiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of benzodiazepines and opioids for patients for whom alternative treatment options are inadequate. [0m
[31mObservational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is [0m
[31mmade to prescribe clonazepam tablets concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of [0m
[31mrespiratory depression and sedation. CLONAZEPAM: warnings: Advise both patients and caregivers about the risks of respiratory depression and sedation when clonazepam tablets are used with opioids [0m[1;31m([0m[31msee[0m
[31mPRECAUTIONS: Information for Patients and PRECAUTIONS: Drug Interactions [0m[1;31m)[0m[31m. Abuse, Misuse, and Addiction: The use of benzodiazepines, including clonazepam tablets, exposes users to the risks of abuse,[0m
[31mmisuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often [0m[1;31m([0m[31mbut not always[0m[1;31m)[0m[31m involve the use of doses greater than the maximum recommended dosage and commonly[0m
[31minvolve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, [0m
[31moverdose, or death [0m[1;31m([0m[31msee DRUG ABUSE AND DEPENDENCE: Abuse [0m[1;31m)[0m[31m . Before prescribing clonazepam tablets and throughout treatment, assess each patientâ€™s risk for abuse, misuse, and addiction [0m[1;31m([0m[31me.g. [0m
[31mCLONAZEPAM: warnings: using a standardized screening tool[0m[1;31m)[0m[31m. Use of clonazepam tablets, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of clonazepam [0m
[31mtablets along with monitoring for signs and symptoms of abuse, misuse, and addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances [0m
[31massociated with abuse, misuse, and addiction [0m[1;31m([0m[31me.g., opioid analgesics, stimulants[0m[1;31m)[0m[31m; and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the [0m
[31mpatient and institute [0m[1;31m([0m[31mor refer them for[0m[1;31m)[0m[31m early treatment, as appropriate. Dependence and Withdrawal Reactions: To reduce the risk of withdrawal reactions, use a gradual taper to discontinue [0m
[31mclonazepam tablets or reduce the dosage [0m[1;31m([0m[31ma patient-specific plan should be used to taper the dose[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION: Discontinuation or Dosage Reduction of Clonazepam Tablets [0m[1;31m)[0m[31m .        [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: boxed_warning: WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and [0m
[31mopioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. [0m
[31mLimit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [0m[1;31m([0m[31msee WARNINGS and PRECAUTIONS [0m[1;31m)[0m[31m. The use of benzodiazepines, [0m
[31mincluding clonazepam tablets, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other[0m
[31mmedications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. CLONAZEPAM: boxed_warning: Before prescribing clonazepam tablets and [0m
[31mthroughout treatment, assess each patientâ€™s risk for abuse, misuse, and addiction [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m . The continued use of benzodiazepines, including clonazepam tablets, may lead to clinically [0m
[31msignificant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of clonazepam [0m
[31mtablets after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue clonazepam tablets[0m
[31mor reduce the dosage [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION and WARNINGS [0m[1;31m)[0m[31m .         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: spl_medguide_table: [0m[1;31m<[0m[1;31mcontent[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these [0m
[31msymptoms.<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mitem[0m[31m><item><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Some people who suddenly stop benzodiazepines have symptoms that can last for several weeks to more than [0m[1;31m12[0m[31m months<[0m[31m/[0m[31mcontent[0m[31m>, including, [0m
[31manxiety, trouble remembering, learning, or concentrating, depression, problems sleeping, feeling like insects are crawling under your skin, weakness, shaking, muscle twitching, burning or prickling [0m
[31mfeeling in your hands, arms, legs or feet, and ringing in your ears. <[0m[31m/[0m[31mitem[0m[31m><item>Physical dependence is not the same as drug addiction. Your healthcare provider can tell you more about the [0m
[31mdifferences between physical dependence and drug addiction.<[0m[31m/[0m[31mitem[0m[31m><item>Do not take more clonazepam tablets than prescribed or take clonazepam tablets for longer than prescribed. CLONAZEPAM: [0m
[31mspl_medguide_table: <list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disc"[0m[31m><item><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Clonazepam tablets can make you sleepy or dizzy and can slow your thinking and motor skills. This may [0m
[31mget better over time.<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mitem[0m[31m><item>Do not drive, operate heavy machinery, or do other dangerous activities until you know how clonazepam tablets affect you. <content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m/[0m[31m><[0m[31m/[0m[31mitem[0m[31m><item>Clonazepam tablets may cause problems with your coordination, especially when you are walking or picking things up. <content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m/[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m
[31mstyleCode[0m[31m=[0m[31m"Disc"[0m[31m><item><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Do not drink alcohol or take other drugs that may make you sleepy or dizzy while taking clonazepam tablets until you talk to your healthcare [0m
[31mprovider.<[0m[31m/[0m[31mcontent[0m[31m>When taken with alcohol or drugs that cause sleepiness or dizziness, clonazepam tablets may make your sleepiness or dizziness worse. CLONAZEPAM: spl_medguide_table: <content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m/[0m[31m><[0m[31m/[0m[31mitem[0m[31m><item><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Like other antiepileptic medicines, clonazepam tablets may cause suicidal thoughts or actions in a very small number of people, about [0m[1;31m1[0m[31m in [0m[1;31m500[0m[31m.[0m
[31mCLONAZEPAM: spl_medguide_table: content><[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Call your healthcare provider right away if you have any of these symptoms, [0m
[31mespecially if they are new, worse, or worry you:<[0m[31m/[0m[31mcontent[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr [0m[31mstyleCode[0m[31m=[0m[31m"Botrule"[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disc"[0m[31m><item>thoughts about [0m
[31msuicide or dying<[0m[31m/[0m[31mitem[0m[31m><item>attempts to commit suicide<[0m[31m/[0m[31mitem[0m[31m><item>new or worse depression<[0m[31m/[0m[31mitem[0m[31m><item>new or worse anxiety<[0m[31m/[0m[31mitem[0m[31m><item>feeling agitated or restless<[0m[31m/[0m[31mitem[0m[31m><item>panic [0m
[31mattacks<[0m[31m/[0m[31mitem[0m[31m><item>trouble sleeping [0m[1;31m([0m[31minsomnia[0m[1;31m)[0m[31m<[0m[31m/[0m[31mitem[0m[31m><item>acting on dangerous impulses<[0m[31m/[0m[31mitem[0m[31m><item>new or worse irritability<[0m[31m/[0m[31mitem[0m[31m><item>an extreme increase in activity and talking [0m
[1;31m([0m[31mmania[0m[1;31m)[0m[31m<[0m[31m/[0m[31mitem[0m[31m><item>acting aggressive, being angry, or violent<[0m[31m/[0m[31m CLONAZEPAM: spl_medguide_table: item><item>other unusual changes in behavior or mood<[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr [0m[31mstyleCode[0m[31m=[0m[31m"Botrule"[0m[31m><td[0m
[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>How can I watch for early symptoms of suicidal thoughts and actions?<[0m[31m/[0m[31mcontent[0m[31m> <list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disc"[0m[31m><item>Pay [0m
[31mattention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings.<[0m[31m/[0m[31mitem[0m[31m><item>Keep all follow-up visits with your healthcare provider as scheduled.<[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[1;31m>[0m[31mCall your[0m
[31mhealthcare provider between visits as needed, especially if you are worried about symptoms. Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or [0m
[31mactions, your healthcare provider may check for other causes.         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m


[31mCONTENT: CLONAZEPAM: warnings: Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages, and [0m
[31mthose who have had longer durations of use. Acute Withdrawal Reactions The continued use of benzodiazepines, including clonazepam tablets, may lead to clinically significant physical dependence. [0m
[31mAbrupt discontinuation or rapid dosage reduction of clonazepam tablets after continued use, or administration of flumazenil [0m[1;31m([0m[31ma benzodiazepine antagonist[0m[1;31m)[0m[31m may precipitate acute withdrawal reactions, [0m
[31mwhich can be life-threatening [0m[1;31m([0m[31me.g., seizures[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee DRUG ABUSE AND DEPENDENCE: Dependence [0m[1;31m)[0m[31m . Protracted Withdrawal Syndrome In some cases, benzodiazepine users have developed a protracted withdrawal [0m
[31msyndrome with withdrawal symptoms lasting weeks to more than [0m[1;31m12[0m[31m months [0m[1;31m([0m[31msee DRUG ABUSE AND DEPENDENCE: Dependence [0m[1;31m)[0m[31m. CLONAZEPAM: warnings: Interference with Cognitive and Motor Performance: Since [0m
[31mclonazepam tablets produce CNS depression, patients receiving this drug should be cautioned against engaging in hazardous occupations requiring mental alertness, such as operating machinery or driving[0m
[31ma motor vehicle. They should also be warned about the concomitant use of alcohol or other CNS-depressant drugs during clonazepam tablets therapy [0m[1;31m([0m[31msee PRECAUTIONS: Drug Interactions and PRECAUTIONS: [0m
[31mInformation for Patients [0m[1;31m)[0m[31m. Suicidal Behavior and Ideation: Antiepileptic drugs [0m[1;31m([0m[31mAEDs[0m[1;31m)[0m[31m, including clonazepam tablets, increase the risk of suicidal thoughts or behavior in patients taking these drugs [0m
[31mfor any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood[0m
[31mor behavior. CLONAZEPAM: warnings: Pooled analyses of [0m[1;31m199[0m[31m placebo-controlled clinical trials [0m[1;31m([0m[31mmono- and adjunctive therapy[0m[1;31m)[0m[31m of [0m[1;31m11[0m[31m different AEDs showed that patients randomized to one of the AEDs had [0m
[31mapproximately twice the risk [0m[1;31m([0m[31madjusted Relative Risk [0m[1;31m1.8[0m[31m, [0m[1;31m95[0m[31m% CI:[0m[1;31m1.2[0m[31m, [0m[1;31m2.7[0m[1;31m)[0m[31m of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment [0m
[31mduration of [0m[1;31m12[0m[31m weeks, the estimated incidence rate of suicidal behavior or ideation among [0m[1;31m27[0m[31m,[0m[1;31m863[0m[31m AED-treated patients was [0m[1;31m0.43[0m[31m% compared to [0m[1;31m0.24[0m[31m% among [0m[1;31m16[0m[31m,[0m[1;31m029[0m[31m placebo-treated patients, representing an[0m
[31mincrease of approximately one case of suicidal thinking or behavior for every [0m[1;31m530[0m[31m patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated [0m
[31mpatients, but the number is too small to allow any conclusion about drug effect on suicide. CLONAZEPAM: warnings: The increased risk of suicidal thoughts or behavior with AEDs was observed as early as[0m
[31mone week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond [0m[1;31m24[0m[31m weeks, the risk of suicidal[0m
[31mthoughts or behavior beyond [0m[1;31m24[0m[31m weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs[0m
[31mof varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age [0m[1;31m([0m[1;31m5[0m[31m to [0m[1;31m100[0m[31m years[0m[1;31m)[0m[31m in the[0m
[31mclinical trials analyzed. Table [0m[1;31m1[0m[31m shows absolute and relative risk by indication for all evaluated AEDs. Table [0m[1;31m1[0m[31m. CLONAZEPAM: warnings: Risk by Indication for Antiepileptic Drugs in the Pooled [0m
[31mAnalysis Indication Placebo Drug Patients Relative Risk: Risk Difference: Patients with with Events Per Incidence of Additional Drug Events Per [0m[1;31m1000[0m[31m Patients Events in Drug Patients with [0m[1;31m1000[0m[31m Patients[0m
[31mPatients/Incidence Events per [0m[1;31m1000[0m[31m in Placebo Patients Patients Epilepsy [0m[1;31m1.0[0m[31m [0m[1;31m3.4[0m[31m [0m[1;31m3.5[0m[31m [0m[1;31m2.4[0m[31m Psychiatric [0m[1;31m5.7[0m[31m [0m[1;31m8.5[0m[31m [0m[1;31m1.5[0m[31m [0m[1;31m2.9[0m[31m Other [0m[1;31m1.0[0m[31m [0m[1;31m1.8[0m[31m [0m[1;31m1.9[0m[31m [0m[1;31m0.9[0m[31m Total [0m[1;31m2.4[0m[31m [0m[1;31m4.3[0m[31m [0m[1;31m1.8[0m[31m [0m[1;31m1.9[0m[31m The relative risk for suicidal thoughts[0m
[31mor behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric [0m
[31mindications. CLONAZEPAM: warnings: Anyone considering prescribing clonazepam tablets or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. [0m
[31mEpilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and with an increased risk of suicidal thoughts and behavior. Should suicidal [0m
[31mthoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated. Patients, [0m
[31mtheir caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the [0m
[31msigns and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported [0m
[31mimmediately to healthcare providers. CLONAZEPAM: warnings: Neonatal Sedation and Withdrawal Syndrome: Use of clonazepam tablets late in pregnancy can result in sedation [0m[1;31m([0m[31mrespiratory depression, [0m
[31mlethargy, hypotonia[0m[1;31m)[0m[31m and/or withdrawal symptoms [0m[1;31m([0m[31mhyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties[0m[1;31m)[0m[31m in the neonate [0m[1;31m([0m[31msee PRECAUTIONS: Pregnancy [0m[1;31m)[0m[31m. [0m
[31mMonitor neonates exposed to clonazepam tablets during pregnancy or labor for signs of sedation and monitor neonates exposed to clonazepam tablets during pregnancy for signs of withdrawal; manage these[0m
[31mneonates accordingly.         [0m
[31mSOUR[0m[1;31mCE:C[0m[31mLONAZEPAM label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Clonazepam has been reported to cause bleeding dermal as an infrequent adverse event, which is defined as occurring in [0m[1;32m1[0m[32m/[0m[1;32m100[0m[32m to [0m[1;32m1[0m[32m/[0m[1;32m1000[0m[32m patients. This suggests that while there is a potential [0m
[32mfor clonazepam to increase the risk of bleeding, it is not a common occurrence.[0m

[32mSOURCE: CLONAZEPAM label[0m
[32mEXTRACT_START_END: Platelet, Bleeding and Clotting Disorders: bleeding dermal[0m[32m...[0m
*[1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Clonazepam has been reported to cause bleeding dermal as an infrequent[0m
[34madverse event, which is defined as occurring in [0m[1;34m1[0m[34m/[0m[1;34m100[0m[34m to [0m[1;34m1[0m[34m/[0m[1;34m1000[0m[34m patients. This suggests that while there is a potential for clonazepam to increase the risk of bleeding, it is not a common occurrence.[0m

[34mSOURCE: CLONAZEPAM label[0m
[34mEXTRACT_START_END: Platelet, Bleeding and Clotting Disorders: bleeding dermal[0m[34m...[0m
 [1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does CLONAZEPAM increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether CLONAZEPAM increases or decreases the risk of bleeding."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that clonazepam has been reported to cause bleeding dermal as an infrequent adverse event, occurring in 1/100 to 1/1000 patients."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"Clonazepam may increase the risk of bleeding, but this is an infrequent side effect."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does CLONAZEPAM increase or decrease the risk of bleeding?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether CLONAZEPAM increases or decreases the risk of bleeding."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that clonazepam has been reported to cause bleeding dermal as an infrequent adverse event, occurring in 1/100 to 1/1000 patients."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"Clonazepam may increase the risk of bleeding, but this is an infrequent side effect."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does CLONAZEPAM increase or decrease the risk of bleeding?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether CLONAZEPAM increases or decreases the risk of bleeding.[0m
[1;31m2[0m[31m. FDAHandler responded that clonazepam has been reported to cause bleeding dermal as an infrequent adverse event, occurring in [0m[1;31m1[0m[31m/[0m[1;31m100[0m[31m to [0m[1;31m1[0m[31m/[0m[1;31m1000[0m[31m patients.[0m
[31m        -----[0m
[31m        Final answer: Clonazepam may increase the risk of bleeding, but this is an infrequent side effect.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-bleeding-CLONAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mClonazepam may increase the risk of bleeding, but this is an infrequent side effect, occurring in [0m[1;32m1[0m[32m/[0m[1;32m100[0m[32m to [0m[1;32m1[0m[32m/[0m[1;32m1000[0m[32m patients.[0m
